Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arrowhead Pharmaceuticals, Inc. - Common Stock
(NQ:
ARWR
)
67.79
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Today 7:30 EST
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
December 23, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
December 22, 2025
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...
Via
MarketMinute
Topics
ETFs
Economy
Intellectual Property
Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target
↗
November 26, 2025
Via
Stocktwits
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 15, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
December 08, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
December 02, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’
↗
September 02, 2025
Via
Stocktwits
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
December 01, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today
↗
November 26, 2025
These are historic days for the company, following its first FDA approval.
Via
The Motley Fool
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval
↗
November 25, 2025
Arrowhead Pharmaceuticals exceeded Q4 2025 revenue expectations, driven by its first FDA-approved drug and strong collaborations, marking its shift to a commercial-stage company.
Via
Chartmill
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript
↗
November 25, 2025
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
November 25, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
November 24, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 19, 2025
Via
Benzinga
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder
↗
November 18, 2025
Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.
Via
Benzinga
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
November 18, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial
↗
November 11, 2025
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.
Via
Benzinga
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
November 06, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Privium Fund Management Sells Into Strength in Pharma Stock
↗
November 04, 2025
Privium Fund Management Sells Into Strength in Pharma Stock
Via
The Motley Fool
Topics
Regulatory Compliance
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
November 04, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 28, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
October 21, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
October 07, 2025
From
Arrowhead Pharmaceuticals
Via
Business Wire
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
↗
September 29, 2025
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
Via
Benzinga
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
September 11, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
September 10, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
↗
September 05, 2025
The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology.
Via
The Motley Fool
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
↗
September 02, 2025
Via
Benzinga
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion
↗
September 02, 2025
Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
